Prolia (Denosumab) HSA/FSA Eligibility and Submission: Complete 2026 Guide

Is Prolia HSA/FSA Eligible?

Prolia (denosumab) qualifies as a reimbursable medical expense under both HSAs and FSAs. The IRS defines eligible expenses in Publication 502 as amounts paid for the diagnosis, cure, mitigation, treatment, or prevention of disease. A prescribed medication administered by a licensed clinician satisfies that definition directly. Because Prolia is always physician-prescribed and typically administered in a clinical setting, there is no gray area about eligibility.

The IRS Rule That Makes This Work

IRS Publication 502 states that prescription drugs and insulin are deductible medical expenses. The same standard governs HSA and FSA reimbursements under IRC Section 213(d). Prolia is dispensed only by prescription, so it clears this bar on every administration.

The CARES Act of 2020 expanded the list of over-the-counter items eligible for HSA/FSA purchase without a prescription, but that expansion did not change the status of prescription injectables like Prolia. Prolia was already fully eligible before 2020 and remains so in 2026. The FDA label for Prolia confirms prescription-only status.

Limited-Purpose FSAs

Patients enrolled in a High Deductible Health Plan (HDHP) sometimes hold a Limited-Purpose FSA alongside their HSA. Limited-Purpose FSAs typically cover only dental and vision costs until the HDHP deductible is met. Prolia, as a prescribed systemic medication, may not qualify under a strict Limited-Purpose FSA unless the plan has been converted to a general-purpose FSA after the deductible is satisfied. Always confirm with your FSA plan administrator before submitting.

Dependent Care FSAs

Dependent Care FSAs cover childcare and adult-care expenses, not medical costs. Prolia cannot be reimbursed from a Dependent Care FSA.

Why Cost Management Matters for Prolia Patients

Prolia's wholesale acquisition cost runs approximately $1,490 per injection as of 2025. Two injections per year means a gross annual drug cost near $2,980 before any insurance or assistance. For patients with high-deductible plans or Medicare coverage gaps, that figure can create genuine access barriers.

Osteoporosis affects roughly 10 million Americans, and another 44 million have low bone density placing them at elevated fracture risk, according to the National Osteoporosis Foundation data cited in this NIH bone health resource. Hip fractures are associated with a 15 to 25% excess mortality risk in the year following the event. A 2023 JAMA Internal Medicine analysis confirmed that cost-related non-adherence to osteoporosis medications is a leading driver of preventable fractures in Medicare-aged women.

Stopping denosumab without a transition to bisphosphonate therapy carries its own risk. The FREEDOM extension trial, which enrolled 4,550 participants, documented rebound vertebral fractures occurring in up to 7.1% of patients who discontinued without follow-on therapy, with a median time to fracture of approximately 9 months after the last injection. That dataset is summarized in the FDA's approved Prolia prescribing information. Cost barriers that cause missed injections are therefore a direct clinical safety concern, not merely a financial inconvenience.

What Prolia Treats

Prolia is FDA-approved for four indications. It targets postmenopausal osteoporosis in women at high fracture risk, glucocorticoid-induced osteoporosis in men and women initiating or continuing prednisone at 7.5 mg/day or higher for at least 6 months, bone loss associated with androgen deprivation therapy in men with non-metastatic prostate cancer, and bone loss associated with adjuvant aromatase inhibitor therapy in women with breast cancer. The key FREEDOM trial (N=7,808) demonstrated a 68% relative risk reduction in new vertebral fractures at 36 months compared with placebo (P<0.001).

How to Submit a Prolia Claim to Your HSA or FSA

The submission process differs slightly depending on whether Prolia is obtained through a specialty pharmacy (self-administered is rare but possible) or administered in a physician's office or infusion clinic.

Step 1: Get an Itemized Receipt or EOB

The single most common reason HSA/FSA claims are denied is missing documentation. You need one of the following:

• Pharmacy receipt showing the drug name (denosumab or Prolia), the dispensing date, the quantity, and the amount you paid out of pocket.
• Explanation of Benefits (EOB) from your insurer, showing the date of service, the drug or procedure billed, the allowed amount, what insurance paid, and your patient responsibility.
• Superbill or office receipt from the administering clinic, including the J-code (J0897 for denosumab) or NDC, the date, and the patient's cost.

Step 2: Submit Through Your Plan Administrator's Portal

Most HSA and FSA administrators accept digital uploads through a web portal or mobile app. Log in, select "Submit a Claim," attach the receipt or EOB, and enter the amount. Processing typically takes 3 to 5 business days. Keep the original documentation for at least 3 years in case of IRS audit.

Step 3: Reimbursement or Direct Payment

If you already paid out of pocket, you will receive a reimbursement to your linked bank account or a check. If your HSA offers a debit card, you can also pay the clinic or pharmacy directly at the time of service, skipping the reimbursement step entirely.

Using an HSA Debit Card at the Clinic

Physician offices and hospital outpatient pharmacies that administer Prolia generally accept HSA/FSA debit cards at checkout. Confirm with the front desk before your appointment. If the card is declined (merchant category codes occasionally cause issues), pay out of pocket and submit for reimbursement immediately.

Amgen SupportPlus Copay Program

The Amgen SupportPlus program is the most powerful single tool for commercially insured patients to reduce Prolia costs before HSA/FSA funds are even involved.

Eligibility Requirements

To qualify for Amgen SupportPlus in 2026, patients must:

1. Have commercial, private, or employer-sponsored insurance (Medicare, Medicaid, and other government programs are excluded by law).
2. Be a U.S. Resident.
3. Have a valid Prolia prescription from a licensed prescriber.

Eligible patients may pay as little as $0 per injection, with Amgen covering up to a defined maximum benefit per calendar year. The program resets annually on January 1. Enrollment is free and can be completed at amgensupportplus.com or by calling 1-888-772-6436.

How Copay Card Savings Interact With HSA/FSA Rules

A 2024 IRS guidance update clarified that copay assistance amounts paid by a manufacturer card do not count as amounts "paid by the taxpayer" and therefore cannot be submitted for HSA/FSA reimbursement. You may only claim the portion you personally paid after the copay card is applied. For most commercially insured patients using SupportPlus, that personal payment may be $0, leaving no HSA/FSA submission to make. However, if a deductible phase means you owe an amount above the copay cap, that remainder is fully submittable to your HSA or FSA.

The IRS Notice 2010-59 framework and subsequent guidance govern this interaction.

Medicare, Medicaid, and Government-Insured Patients

Federal anti-kickback statutes prohibit pharmaceutical manufacturers from offering copay assistance to patients whose primary coverage is a government program. If your primary payer is Medicare Part B (which covers Prolia under the medical benefit, not the pharmacy benefit), Medicare Part D, Medicaid, TRICARE, or VA, you cannot use the Amgen SupportPlus copay card.

Medicare Part B Coverage of Prolia

Prolia administered in a physician's office is generally billed under Medicare Part B as a drug under J0897. Medicare Part B covers 80% of the allowed amount after the deductible, leaving a 20% coinsurance. On a $1,490 list price, that 20% is approximately $298 per injection. Medicare Supplemental Insurance (Medigap) policies may cover all or part of that 20%. CMS guidance on Part B drug coverage is available here.

HSA funds cannot be used by Medicare enrollees to pay premiums for most Medicare coverage, but they can still be used for Medicare cost-sharing amounts, including Part B coinsurance. If you have an existing HSA balance from your pre-Medicare working years, you may use those accumulated funds to pay your Prolia Part B coinsurance. You cannot contribute new funds to an HSA after enrolling in Medicare Part A or B.

Amgen FIRST STEP Patient Assistance Program

For patients who are uninsured or whose government insurance leaves a gap that no other program fills, Amgen offers the FIRST STEP program. Qualifying patients may receive Prolia at no cost. Income and insurance eligibility thresholds apply and are verified annually. Applications are available through Amgen's patient assistance page or by calling 1-888-772-6436.

Other Strategies to Reduce Prolia Out-of-Pocket Costs

NeedyMeds and RxAssist Databases

NeedyMeds (needymeds.org) and RxAssist (rxassist.org) maintain updated databases of manufacturer assistance programs, state pharmaceutical assistance programs, and disease-specific foundations. These can be particularly valuable for Medicare patients excluded from manufacturer copay cards.

State Pharmaceutical Assistance Programs (SPAPs)

Several U.S. States operate SPAPs that supplement Medicare drug costs for low-income seniors. Eligibility varies by state. The Medicare Interactive SPAP resource provides a state-by-state summary.

Disease-Specific Foundations

The HealthWell Foundation and Patient Advocate Foundation both maintain osteoporosis disease funds that may provide grants toward Prolia costs for qualifying patients. Fund availability fluctuates; applications must be submitted when funds are open.

Biosimilar Denosumab Options

The FDA approved Jubbonti and Wyost, denosumab-bbdz biosimilars from Sandoz, in June 2024. The FDA biosimilar approval announcement is available here. Additional denosumab biosimilars are in the FDA review pipeline. As biosimilar market share grows through 2026, negotiated prices may fall meaningfully below Prolia's WAC. HSA/FSA eligibility applies equally to FDA-approved biosimilar versions of denosumab. Ask your prescriber whether a biosimilar is clinically appropriate for your situation.

The table below outlines the cost-reduction pathway by insurance type. Use it as a triage checklist before your next injection appointment.

| Insurance Type | Best First Step | HSA/FSA Applicable? | |---|---|---| | Commercial/Employer | Amgen SupportPlus copay card | Yes, for remaining out-of-pocket | | HDHP + HSA | Amgen SupportPlus, then HSA for remainder | Yes | | Medicare Part B | Medigap coinsurance coverage | Yes, for Part B coinsurance from existing HSA | | Medicare Part D (rare) | SPAP, then HealthWell Foundation | Yes, from existing HSA balance | | Medicaid | Covered at low/no cost; verify formulary | Rarely applicable | | Uninsured | Amgen FIRST STEP program | Yes, for any remaining balance |

Clinical Context: Why Adherence Has to Be the Priority

Denosumab works by binding RANK ligand and blocking osteoclast formation, thereby reducing bone resorption. The mechanism is described in detail in the original FREEDOM trial publication in the New England Journal of Medicine (Cummings et al., 2009, N=7,808), which showed a 68% relative risk reduction in vertebral fractures at 36 months. The drug has a fixed 6-month dosing interval and no meaningful flexibility. A missed injection by more than a few weeks can trigger the rebound resorption phenomenon described above.

Endocrine Society Clinical Practice Guideline Recommendation

The 2020 Endocrine Society Clinical Practice Guideline on osteoporosis in postmenopausal women, published in the Journal of Clinical Endocrinology and Metabolism, states: "We suggest that patients treated with denosumab who wish to discontinue therapy receive subsequent antiresorptive therapy to prevent rapid bone loss and rebound vertebral fractures." (Eastell et al., JCEM 2019) That guidance underscores why uninterrupted access to Prolia, including affordable access, is a clinical necessity rather than a preference.

The American Society for Bone and Mineral Research (ASBMR) published a special report reinforcing that at least one dose of a bisphosphonate (typically zoledronic acid 5 mg IV) should be administered 6 months after the last denosumab injection if discontinuation is planned. That report appears in the Journal of Bone and Mineral Research.

Fracture Risk Scoring to Confirm Indication

Before initiating or continuing Prolia, most guidelines recommend a FRAX score calculation to confirm 10-year fracture probability. The National Osteoporosis Foundation threshold for pharmacologic treatment is a 10-year major osteoporotic fracture probability at or above 20%, or a hip fracture probability at or above 3%. The FRAX algorithm and supporting data are maintained by the University of Sheffield and referenced in USPSTF osteoporosis screening guidance. Documenting FRAX in the chart also strengthens the medical necessity record that insurers and HSA/FSA auditors may request.

Record-Keeping for Tax and Audit Purposes

The IRS can audit HSA distributions up to 3 years after the filing date of the return in which the distribution was taken. Keep the following for every Prolia injection reimbursed through an HSA or FSA:

• Original receipt or EOB showing patient-paid amount.
• Prescription documentation (prescription printout or chart note with drug name and prescribing provider).
• Proof of payment (bank statement, HSA debit card statement, or reimbursement deposit confirmation).

Store these as PDFs in a dedicated folder. Your HSA custodian's portal typically retains records for only 7 years, but personal retention is your own responsibility. IRS Publication 969 governs HSA record-keeping requirements.

Practical Checklist Before Your Next Prolia Appointment

1. Confirm your HSA or FSA balance at least 2 weeks before the injection date.
2. Enroll in or renew Amgen SupportPlus if you carry commercial insurance.
3. Ask the clinic's billing coordinator which payment method they accept (HSA debit card vs. Reimbursement).
4. Request an itemized receipt or J0897 superbill immediately after the visit.
5. Submit the HSA/FSA claim within your plan's submission deadline (most plans allow up to 90 days post-service for FSAs; HSAs have no deadline but immediate submission simplifies audit trails).
6. Confirm the transition plan with your prescriber if you are considering stopping Prolia, because bisphosphonate bridging therapy should be scheduled before the final injection is missed.